Lexicon Pharmaceuticals, Inc. (LXRX)
Nasdaq · Healthcare · Biotechnology
$1.74−4.40%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $774M
- 52-week range
- $1.10 – $2.68
- 52-week change
- +19.74%
- EPS (trailing)
- −$0.16
- Analyst rating
- 1.8 Buy
- Next earnings
- Nov 5, 2026
Fiscal year to Dec 2025
- Revenue
- $49.8M (+60.24%)
- Net income
- −$50.3M
- Operating margin
- −98.2%
- Diluted EPS
- −$0.14
- Free cash flow
- −$67.8M
From the company’s annual report on SEC EDGAR.
About Lexicon Pharmaceuticals, Inc.
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercializes INPEFA (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, CKD, and other cardiovascular risk factors. In addition, the company develops LX9851, an orally-delivered small molecule drug candidate for the treatment of obesity and associated cardiometabolic disorders, and pilavapadin (LX9211), an orally-delivered small molecule drug candidate for the treatment of neuropathic pain. It has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Headquarters: The Woodlands, United States · 81 employees · lexpharma.com